Equities Analysts Offer Predictions for Evotec Q3 Earnings

Evotec AG (NASDAQ:EVO) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Evotec in a research note issued to investors on Thursday, November 6th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of $0.01 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.41) per share.

Other analysts have also issued reports about the stock. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Evotec in a research note on Wednesday, September 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Evotec in a report on Wednesday. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Evotec presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Evotec Price Performance

Shares of EVO stock traded down $0.29 on Friday, reaching $3.02. 41,128 shares of the company’s stock were exchanged, compared to its average volume of 84,093. The company’s fifty day simple moving average is $3.75 and its 200 day simple moving average is $3.94. Evotec has a 52 week low of $2.84 and a 52 week high of $5.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.58 and a quick ratio of 1.49.

Institutional Investors Weigh In On Evotec

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. DCF Advisers LLC lifted its holdings in Evotec by 227.0% in the first quarter. DCF Advisers LLC now owns 751,579 shares of the company’s stock valued at $2,510,000 after acquiring an additional 521,708 shares during the last quarter. Valeo Financial Advisors LLC purchased a new stake in shares of Evotec in the 2nd quarter valued at approximately $43,000. WCM Investment Management LLC acquired a new stake in Evotec in the 2nd quarter valued at approximately $1,239,000. ABC Arbitrage SA acquired a new position in Evotec during the first quarter worth $260,000. Finally, UMB Bank n.a. purchased a new stake in shares of Evotec in the 2nd quarter valued at $56,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.